Climb Bio Inc (CLYM) USD0.0001

Sell:$1.13Buy:$1.14$0.02 (1.30%)

Prices delayed by at least 15 minutes
Sell:$1.13
Buy:$1.14
Change:$0.02 (1.30%)
Prices delayed by at least 15 minutes
Sell:$1.13
Buy:$1.14
Change:$0.02 (1.30%)
Prices delayed by at least 15 minutes

Company Information

About this company

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Key people

Andrew David Levin
Chairman of the Board
Aoife M. Brennan
President, Chief Executive Officer, Director
Brett I. Kaplan
Principal Financial Officer, Chief Operating Officer
Liam T. Ratcliffe
Lead Independent Director
Bo Cumbo
Director
Kim Cobleigh Drapkin
Director
Stephen Thomas
Director
Judith A. Dunn
Independent Director
Click to see more

Key facts

  • EPIC
    CLYM
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US28658R1068
  • Market cap
    $81.65m
  • Employees
    17
  • Shares in issue
    67.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.